Anton Hagenbeek

Fair Pricing of Innovative Medicines: An EHA Position Paper

Carin A. Uyl-de Groot, Anton Hagenbeek, John G. Gribben, 2020, HemaSphere.

Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols

Daphne de Jong, Anton Hagenbeek, J. Raemaekers, 2009, Haematologica.

Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular Cytotoxicity

Anton Hagenbeek, A. Hagenbeek, Tom van Meerten, 2006, Clinical Cancer Research.

CD20-targeted therapy: the next generation of antibodies.

Anton Hagenbeek, A. Hagenbeek, Tom van Meerten, 2010, Seminars in hematology.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Andrew Lister, Anne Sonet, Hervé Tilly, 2011, The Lancet.

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium.

Andrew Lister, Birgitta Sander, Edie Weller, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

Max Wolf, Ivana Teodorovic, Randy D Gascoyne, 2006, Blood.

Revised response criteria for malignant lymphoma.

Sigrid Stroobants, Bruce D Cheson, Lena Specht, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.